MAWAG
BDTX icon

Mid-American Wealth Advisory Group’s Black Diamond Therapeutics BDTX Stock Holding History

Mid-American Wealth Advisory Group’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-19
Closed -$47 – 75
2025
Q2 		$47 Buy
+19
New +$37 ﹤0.01% 338

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Mid-American Wealth Advisory Group's BDTX Position: Q3 2025 in Review

Mid-American Wealth Advisory Group sold out of Black Diamond Therapeutics (BDTX) in Q3 2025, closing a stake of 19 shares — an estimated $47 sold.

Mid-American Wealth Advisory Group first reported a position in BDTX in Q2 2025 and held it in 1 quarter. The position peaked at $47 in Q2 2025. 91 funds tracked by Wall St. Rank hold BDTX as of Q3 2025.

  • Mid-American Wealth Advisory Group reported no remaining Black Diamond Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Mid-American Wealth Advisory Group sold 19 Black Diamond Therapeutics shares in Q3 2025, an estimated $47.
  • Mid-American Wealth Advisory Group first reported a position in Black Diamond Therapeutics in Q2 2025 and held it in 1 quarter.
  • Mid-American Wealth Advisory Group's Black Diamond Therapeutics position peaked at $47 in Q2 2025.
  • 91 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2025.

Based on Mid-American Wealth Advisory Group's 13F filing for Q3 2025, filed 20 Oct 2025.